Biotechnology company, successor to Intrexon
3 AI-extracted insights from 1 source — podcasts, YouTube channels, and X/Twitter accounts.
Not enough scored insights about Precigen Inc. in the last 30 days yet.
The 1 sources with the most insights about Precigen Inc. on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Speaker is bullish following a surprise early FDA approval and sees significant long-term revenue potential, but notes the company will likely need to raise capital.
The speaker is taking a 'very small, long position' not out of conviction, but as a way to force deeper research and monitoring of the stock.
Presents a speculative opportunity with a binary PDUFA date; the bull case rests on strong clinical data, while the bear case is rooted in the company's poor historical reputation.
Speaker is bullish following a surprise early FDA approval and sees significant long-term revenue potential, but notes the company will likely need to raise capital.
The speaker is taking a 'very small, long position' not out of conviction, but as a way to force deeper research and monitoring of the stock.
Presents a speculative opportunity with a binary PDUFA date; the bull case rests on strong clinical data, while the bear case is rooted in the company's poor historical reputation.
Other assets that creators frequently mention in the same content as Precigen Inc..
The most active sources covering Precigen Inc. (PGEN) on Kazuha are @realmartinshkreli. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 3 AI-extracted insights about Precigen Inc. (PGEN) from 1 different source. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Precigen Inc. (PGEN) most frequently also discuss IONQ, QBTS, NVDA, SRPT, NVO. See the "Discussed alongside" section above for full asset pages.